The paper reports a 65-year-old woman with prior breast and renal cancer and biopsy-proven cutaneous, ocular, and pulmonary sarcoidosis who was not receiving immunosuppressive therapy due to low disease activity. She presented with progressive speech, reading, and writing difficulties; MRI showed a DWI/FLAIR-hyperintense left temporo-occipital white matter lesion that enlarged over weeks. Admission labs showed elevated sIL-2R (2350 U/mL) and ACE (45.8 U/L); CSF showed elevated protein (59 mg/dL), Ξ²2-microglobulin (5.51 mg/mL), sIL-2R (195 U/mL), and a CD4/8 ratio of 10.4, with positive oligoclonal bands. These markers were interpreted as consistent with neurosarcoidosis activity, while cultures were negative for bacterial and acid-fast organisms. The paper's central claim is that because PML was plausible in a progressively worsening parenchymal lesion, an early brain biopsy was performed, enabling histopathologic diagnosis of PML (JCV-associated demyelination) before any escalation of immunosuppressive therapy for presumed sarcoidosis, and targeted PML therapy then produced a favorable prognosis .
Reported observations vs. author interpretations: The biopsy findings and lab values are direct observations; the inference that early biopsy caused the favorable prognosis is an author interpretation that a single case cannot test. Limitations and blind spots: (1) n=1 with no control arm; PML survival is highly variable, and isolated non-HIV PML cases can improve spontaneously. (2) The exact "appropriate therapy" regimen is not fully specified in the available text, limiting reproducibility. (3) The T-cell/sarcoidosis immune milieu could itself have modified PML severity; the paper does not disentangle this confounder. (4) Retrospective narrative timing (symptoms in November/January, referral Day 1 in February) leaves the actual biopsy-to-outcome interval uncertain. (5) Prior malignancies add immunologic context not discussed in depth. Confidence in the descriptive findings is moderate; confidence in the causal claim is low.
The broader clinical lessonβconsider PML and biopsy early in progressive white-matter lesions of sarcoidosis patients before escalating immunosuppressionβis biologically coherent and aligns with the known risk of PML under immunosuppression, but it should be regarded as a hypothesis-generating observation, not evidence-level guidance.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.